Sugi Predict

Sugi Predict / Compounds / SCHEMBL6233467

SCHEMBL6233467

SCHEMBL6233467

CCOC(=O)COCCOCCOCCOCCOCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ STAT3 P40763 2/20 0.43
▸ ALDH1A1 P00352 6/20 0.42
▸ POLB P06746 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ RECQL P46063 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ SIRT5 Q9NXA8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23636475 1.00 GAA (0.47) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL17940927 1.00 GAA (0.47) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL21479430 1.00 GAA (0.47) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL17940959 1.00 GAA (0.47) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL23636404 1.00 GAA (0.47) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL2709615 0.99 GAA (0.48) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL17941052 0.96 GAA (0.44) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL31425361 0.93 GAA (0.44) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL17941048 0.92 GAA (0.45) GAANPSR1STAT3ALDH1A1POLB
SCHEMBL4589079 0.90 GAA (0.46) GAANPSR1STAT3ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-07-22 — — US disclosed
US-11066391-B1 Atorvastatin derived HMG-CoA reductase degradation inducing compound UPPTHERA (KR) 2021-07-20 — — US disclosed
US-10994015-B2 EGFR proteolysis targeting chimeric molecules and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-05-04 — — US disclosed
CN-110753693-A EGFR proteolytic targeting chimeric molecules and related methods of use 阿尔维纳斯运营股份有限公司 2020-02-04 — — CN disclosed
EP-3559002-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2019-10-30 — — EP disclosed
WO-2018119441-A9 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 — — WO disclosed
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-07-12 — — US disclosed
WO-2018119441-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-28 — — WO disclosed
US-6908989-B2 Process for the production of perbenzylated 1-O-glycosides SCHERING AG (DE) 2005-06-21 — — US disclosed
EP-1397376-B1 METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES SCHERING AG (DE) 2005-05-04 — — EP disclosed
EP-1397376-A1 METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2004-03-17 — — EP disclosed
EP-1261614-B1 METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES SCHERING AG (DE) 2004-01-07 — — EP disclosed
US-6545135-B2 Alkylation SCHERING AKTIENGESELLSCHAFT (DE) 2003-04-08 — — US disclosed
US-20030055242-A1 Process for the production of perbenzylated 1-O-glycosides BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2003-03-20 — — US disclosed
WO-2002102816-A1 METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2002-12-27 — — WO disclosed
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides SCHERING AKTIENGESELLSCHAFT 2002-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055242-A1 Process for the production of perbenzylated 1-O-glycosides MAN1B1, STT3B, OSTC GAA 187/4885NPSR1 4387/4885STAT3 2885/4885
US-10994015-B2 EGFR proteolysis targeting chimeric molecules and associated methods of use EGFR, ERBB2, ERBB3 GAA 224/4885NPSR1 2359/4885STAT3 944/4885
US-11066391-B1 Atorvastatin derived HMG-CoA reductase degradation inducing compound HMGCR, LDLR, HMGB2 GAA 491/4885NPSR1 4041/4885STAT3 4491/4885
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE EGFR, ERBB2, ERBB3 GAA 224/4885NPSR1 2359/4885STAT3 944/4885
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE TBK1, EGFR, CBL GAA 251/4885NPSR1 3387/4885STAT3 1217/4885
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides STT3B, MAN1B1, OSTC GAA 153/4885NPSR1 4425/4885STAT3 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.